To use all functions of this page, please activate cookies in your browser.
With an accout for my.chemeurope.com you can always see everything at a glance – and you can configure your own website and individual newsletter.
- My watch list
- My saved searches
- My saved topics
- My newsletter
Tibotec is a pharmaceutical company with a focus on research and development for the treatment of infectious diseases such as HIV (AIDS), and Hepatitis C. The company develops antiretroviral drugs for the treatment of AIDS.
Additional recommended knowledge
In 1994, Rudi Pauwels (Rega Institute for Medical Research) founded Tibotec, together with his wife Carine Claeys, and their first co-workers Marie-Pierre de Béthune, Kurt Hertogs, and Hilde Azijn. In 1995 Paul Stoffels (Janssen Pharmaceutica) joins Tibotec. The company was acquired by Johnson & Johnson in April 2002. The name of the company is derived from the tetrahydro-imidazo[4,5,1-jk][1,4]-benzodiazepine-2(1H)-one and -thione (TIBO) compounds discovered at the Rega Institute for Medical Research (Belgium).
Tibotec licensed TMC120, a NNRTI, to the International Partnership for Microbicides for its development as a vaginal microbicide in March 2004.
William C. Weldon, Chairman & CEO
Past CEOs and presidents: Robert Wood Johnson I • James Wood Johnson • Robert Wood Johnson II • Robert Wood Johnson III • Philip B. Hofmann • Richard B. Sellars • James E. Burke • Ralph S. Larsen
Acuvue • Aveeno • Band-Aid • Carefree • Clean & Clear • Johnson's Baby • K-Y • Neutrogena • OneTouch • Rembrandt • Stayfree • Tylenol
Stock symbol: NYSE: JNJ · Website: www.jnj.com